293 related articles for article (PubMed ID: 33497524)
21. A tailored Cln3
Langin L; Johnson TB; Kovács AD; Pearce DA; Weimer JM
Sci Rep; 2020 Jun; 10(1):10591. PubMed ID: 32601357
[TBL] [Abstract][Full Text] [Related]
22. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis.
Drack AV; Miller JN; Pearce DA
J Child Neurol; 2013 Sep; 28(9):1112-6. PubMed ID: 23877479
[TBL] [Abstract][Full Text] [Related]
23. Immunochemical localization of the Batten disease (CLN3) protein in retina.
Katz ML; Gao CL; Prabhakaram M; Shibuya H; Liu PC; Johnson GS
Invest Ophthalmol Vis Sci; 1997 Oct; 38(11):2375-86. PubMed ID: 9344361
[TBL] [Abstract][Full Text] [Related]
24. First case of genetically confirmed CLN3 disease in Chinese with cDNA sequencing revealing pathogenicity of a novel splice site variant.
Lau NKC; Ching CK; Lee HHC; Chak WKM; Kwan Shing N; Hanchard NA; Mak CM
Clin Chim Acta; 2018 Nov; 486():151-155. PubMed ID: 30053402
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic efficacy of antisense oligonucleotides in mouse models of CLN3 Batten disease.
Centa JL; Jodelka FM; Hinrich AJ; Johnson TB; Ochaba J; Jackson M; Duelli DM; Weimer JM; Rigo F; Hastings ML
Nat Med; 2020 Sep; 26(9):1444-1451. PubMed ID: 32719489
[TBL] [Abstract][Full Text] [Related]
26. Molecular mechanisms of the juvenile form of Batten disease: important role of MAPK signaling pathways (ERK1/ERK2, JNK and p38) in pathogenesis of the malady.
Shematorova EK; Shpakovski DG; Chernysheva AD; Shpakovski GV
Biol Direct; 2018 Sep; 13(1):19. PubMed ID: 30621751
[TBL] [Abstract][Full Text] [Related]
27. Ocular morphology and function in juvenile neuronal ceroid lipofuscinosis (CLN3) in the first decade of life.
Preising MN; Abura M; Jäger M; Wassill KH; Lorenz B
Ophthalmic Genet; 2017; 38(3):252-259. PubMed ID: 27486012
[TBL] [Abstract][Full Text] [Related]
28. A novel deletion variant in CLN3 with highly variable expressivity is responsible for juvenile neuronal ceroid lipofuscinoses.
Gilani N; Razmara E; Ozaslan M; Abdulzahra IK; Arzhang S; Tavasoli AR; Garshasbi M
Acta Neurol Belg; 2021 Jun; 121(3):737-748. PubMed ID: 33783722
[TBL] [Abstract][Full Text] [Related]
29. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X).
Sarpong A; Schottmann G; Rüther K; Stoltenburg G; Kohlschütter A; Hübner C; Schuelke M
Clin Genet; 2009 Jul; 76(1):38-45. PubMed ID: 19489875
[TBL] [Abstract][Full Text] [Related]
30. A novel porcine model of CLN3 Batten disease recapitulates clinical phenotypes.
Swier VJ; White KA; Johnson TB; Wang X; Han J; Pearce DA; Singh R; Drack AV; Pfeifer W; Rogers CS; Brudvig JJ; Weimer JM
Dis Model Mech; 2023 Aug; 16(8):. PubMed ID: 37305926
[TBL] [Abstract][Full Text] [Related]
31. Defective lysosomal arginine transport in juvenile Batten disease.
Ramirez-Montealegre D; Pearce DA
Hum Mol Genet; 2005 Dec; 14(23):3759-73. PubMed ID: 16251196
[TBL] [Abstract][Full Text] [Related]
32. Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene.
Sondhi D; Scott EC; Chen A; Hackett NR; Wong AM; Kubiak A; Nelvagal HR; Pearse Y; Cotman SL; Cooper JD; Crystal RG
Hum Gene Ther; 2014 Mar; 25(3):223-39. PubMed ID: 24372003
[TBL] [Abstract][Full Text] [Related]
33. Splicing variants in sheep CLN3, the gene underlying juvenile neuronal ceroid lipofuscinosis.
Oswald MJ; Palmer DN; Damak S
Mol Genet Metab; 1999 Jun; 67(2):169-75. PubMed ID: 10356317
[TBL] [Abstract][Full Text] [Related]
34. Role of the Lysosomal Membrane Protein, CLN3, in the Regulation of Cathepsin D Activity.
Cárcel-Trullols J; Kovács AD; Pearce DA
J Cell Biochem; 2017 Nov; 118(11):3883-3890. PubMed ID: 28390177
[TBL] [Abstract][Full Text] [Related]
35. Loss of the Batten disease gene CLN3 prevents exit from the TGN of the mannose 6-phosphate receptor.
Metcalf DJ; Calvi AA; Seaman MNj; Mitchison HM; Cutler DF
Traffic; 2008 Nov; 9(11):1905-14. PubMed ID: 18817525
[TBL] [Abstract][Full Text] [Related]
36. Deterioration of visual quality and acuity as the first sign of ceroid lipofuscinosis type 3 (CLN3), a rare neurometabolic disease.
Purzycka-Olewiecka JK; Hetmańczyk-Sawicka K; Kmieć T; Szczęśniak D; Trubicka J; Krawczyński M; Pronicki M; Ługowska A
Metab Brain Dis; 2023 Feb; 38(2):709-715. PubMed ID: 36576693
[TBL] [Abstract][Full Text] [Related]
37. Mutated genes in juvenile and variant late infantile neuronal ceroid lipofuscinoses encode lysosomal proteins.
Vesa J; Peltonen L
Curr Mol Med; 2002 Aug; 2(5):439-44. PubMed ID: 12125809
[TBL] [Abstract][Full Text] [Related]
38. Altered gene expression in the eye of a mouse model for batten disease.
Chattopadhyay S; Kingsley E; Serour A; Curran TM; Brooks AI; Pearce DA
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2893-905. PubMed ID: 15326100
[TBL] [Abstract][Full Text] [Related]
39. Loss of Cln3 function in the social amoeba Dictyostelium discoideum causes pleiotropic effects that are rescued by human CLN3.
Huber RJ; Myre MA; Cotman SL
PLoS One; 2014; 9(10):e110544. PubMed ID: 25330233
[TBL] [Abstract][Full Text] [Related]
40. Detailed Clinical Phenotype and Molecular Genetic Findings in CLN3-Associated Isolated Retinal Degeneration.
Ku CA; Hull S; Arno G; Vincent A; Carss K; Kayton R; Weeks D; Anderson GW; Geraets R; Parker C; Pearce DA; Michaelides M; MacLaren RE; Robson AG; Holder GE; Heon E; Raymond FL; Moore AT; Webster AR; Pennesi ME
JAMA Ophthalmol; 2017 Jul; 135(7):749-760. PubMed ID: 28542676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
